Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

On May 1, 2026, Eupraxia Pharmaceuticals Inc. announced the appointment of Dr. Jeymi Tambiah as its new Chief Medical Officer (CMO). Dr. Tambiah, a Board Certified Cardiothoracic Surgeon with over 18 years of experience in clinical development and regulatory strategy, succeeds Dr. Mark Kowalski, who is retiring. Dr. Kowalski will remain with the company as a senior consultant to assist with the transition. Dr. Tambiah joins Eupraxia at a critical juncture as the company advances its lead candidate, EP-104GI, in the RESOLVE Phase 1b/2 trial for Eosinophilic Esophagitis (EoE). His background in immunology and late-stage clinical development is expected to bolster the company's gastroenterology pipeline and the expansion of its proprietary Diffusphere™ technology. The filing also highlights Eupraxia's broader pipeline, including EP-104IAR for knee osteoarthritis pain, which recently met its primary endpoint in a Phase 2b trial. The company expects several near-term data catalysts related to the RESOLVE trial.